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1. INTRODUCTION {#agm212023-sec-0005}
===============

Many advanced cancer patients are surviving longer with improvements in anticancer therapy. Pain from bone metastases accounts for 75% of the presenting complaint in these patients[1](#agm212023-bib-0001){ref-type="ref"} and can be a debilitating problem. It is important to manage pain adequately so that these patients can have a good quality of life.

The role of radiotherapy for palliation of painful bone metastases has been well established. It has been shown to provide pain relief in 50%‐80% of treated patients with a complete response rate of 20%‐50%.[2](#agm212023-bib-0002){ref-type="ref"}, [3](#agm212023-bib-0003){ref-type="ref"} Nevertheless, the optimal dose fractionation remains uncertain. Some studies suggested that single fraction radiotherapy is equally effective to multiple fraction in providing pain relief,[4](#agm212023-bib-0004){ref-type="ref"}, [5](#agm212023-bib-0005){ref-type="ref"}, [6](#agm212023-bib-0006){ref-type="ref"}, [7](#agm212023-bib-0007){ref-type="ref"}, [8](#agm212023-bib-0008){ref-type="ref"}, [9](#agm212023-bib-0009){ref-type="ref"}, [10](#agm212023-bib-0010){ref-type="ref"}, [11](#agm212023-bib-0011){ref-type="ref"} while others showed that higher dose fractionation provides more effective pain relief than single fractionation schedule.[12](#agm212023-bib-0012){ref-type="ref"}, [13](#agm212023-bib-0013){ref-type="ref"} Evidence from several studies demonstrated that single fraction radiotherapy may be associated with higher rates of retreatment and pathological fracture postirradiation.[9](#agm212023-bib-0009){ref-type="ref"}, [10](#agm212023-bib-0010){ref-type="ref"}

We conducted this study to compare outcomes between single and multiple fraction palliative radiotherapy in terms of pain response, retreatment rate, and symptomatic skeletal events, and to describe potential factors affecting treatment outcomes in our patients.

2. METHODS {#agm212023-sec-0006}
==========

2.1. Data collection {#agm212023-sec-0007}
--------------------

This is a retrospective analysis of patients with bone metastases treated with external beam radiotherapy in University of Malaya Medical Centre (UMMC) between January 2006 and December 2014. The study was approved by the Medical Ethics Committee of UMMC (201510‐1789). The radiotherapy database was retrieved and screened for patients with bone metastases. Patient case records, medication chart, and radiotherapy treatment sheet were reviewed to identify eligible patients.

Patients were considered eligible for this study if they had histologically proven primary malignancy with radiologically confirmed bone metastasis and received palliative radiotherapy for pain relief. Patients were excluded if the painful site had been irradiated before the study period (ie, before 2006), the presence of spinal cord compression, pathological fracture or history of surgical intervention at treatment site, and nonsolid primary tumor. Each patient was evaluated only once, that is the first radiation treatment for one particular site.

Relevant data collected include patient demographics, primary tumor details, bone metastasis details, pain severity, analgesic consumption, radiotherapy treatment details, adverse events after radiotherapy, use of bone‐targeting agents, systemic therapy, and retreatment details.

Response evaluations were documented at 4, 12, and 24 weeks after radiotherapy. Patients who died within 24 weeks of evaluation period were excluded from this study. Retreatments occurring within the evaluation period were reported as progression at evaluation endpoint and were excluded from further analysis. Retreatment outcomes were not assessed. Results were reported and compared in 2 treatment groups, that is single and multiple fractions.

2.2. Evaluation and definition of response {#agm212023-sec-0008}
------------------------------------------

### 2.2.1. Pain score {#agm212023-sec-0009}

Pain was measured by a 4‐point scale with numbers 1‐4 with pain documented as none---score 1, mild---score 2, moderate---score 3, and severe---score 4.[5](#agm212023-bib-0005){ref-type="ref"}, [14](#agm212023-bib-0014){ref-type="ref"} Partial response was defined as relief of pain by at least ≥1 category (eg, severe to moderate) or score of at least 1 (eg, 4‐3). Complete response was defined as the absence of pain (pain score of 1) at treated site. Progression was considered as an increase in pain score by ≥1 category or the need for retreatment.

### 2.2.2. Analgesic scoring system {#agm212023-sec-0010}

Patient analgesic consumption was recorded and scored as follows: analgesic score 0---analgesic not required, score 1---nonopioid analgesic irregularly required, score 2---nonopioid analgesics regularly required, score 3---oral or parenteral opioids occasionally required, and score 4---oral or parenteral opioids regularly required.[15](#agm212023-bib-0015){ref-type="ref"} The response was defined as a reduction in analgesic score by at least 1 step or an unchanged analgesic score but reduction in daily dose by ≥25%. Progression was defined as an increase in the analgesic score by ≥25% or the need for retreatment. The stable response was defined as a state between response and progression.

### 2.2.3. International consensus endpoints {#agm212023-sec-0011}

The outcomes were further analyzed using International Consensus Endpoints, which incorporates pain score response and analgesic consumption.[16](#agm212023-bib-0016){ref-type="ref"} Complete response was defined as a pain score of 0 at the treated site with no increase in analgesic intake (ie, stable or reducing analgesic intake). Partial response was defined as a reduction in pain score by at least 1 (scale 1‐4) at the treated site without analgesic intake or analgesic reduction by at least 25% from baseline without an increase in pain. Pain progression was defined as an increase in pain score by at least 1 above baseline at the treated site with stable analgesic usage or an increase in analgesic requirement by at least 25% from baseline with stable pain score.

2.3. Statistical methods {#agm212023-sec-0012}
------------------------

The sample size was calculated using Stata software, based on the information gathered from a study by Arcangeli et al.[12](#agm212023-bib-0012){ref-type="ref"} The sample size was calculated on the basis of a 0.05 alpha, with a power 80% and hazard ratio 0.44 (total dose variable). Based on this calculation and accounting for 20% dropout, each treatment arm required 63 patients. Therefore, the minimum sample size required for this study was 126 patients.

Descriptive analysis of all the demographic and outcome variables was performed. Results of the continuous variables were described with mean and standard deviation or median and interquartile range, where appropriate. Results of categorical variables were described with frequency and percentage. Mann‐Whitney *U* test, chi‐square test, and Fisher\'s exact test were used to compare the demographic and predictor variables with the outcome variables. All statistical analysis was performed using Statistical Package for the Social Sciences (SPSS), ver 22.0. Statistical significance was defined as *P* \< .05. Using univariate analysis, all variables were analyzed and variables were considered significant if *P* \< .25 by applying the preliminary main‐effect model. Significant variables were then included in multivariate analysis using the forward and backward logistic regression. Hosmer and Lemeshow test was carried out to test for interaction and multicollinearity between significant variables and is significant for *P* \> .05.

3. RESULTS {#agm212023-sec-0013}
==========

3.1. Overview of patient characteristics {#agm212023-sec-0014}
----------------------------------------

Between January 2006 and December 2014, 584 patients with bone metastases received palliative radiotherapy in University of Malaya Medical Centre (UMMC). Of the 584 case records reviewed, 162 patients were eligible for this study. A total of 422 patients were excluded from analysis due to prior irradiation (n = 4), nonsolid tumor (n = 5), prior surgical intervention with or without pathological fracture (n = 44), spinal cord compression (n = 113), death within 24 weeks of study period (n = 12), lost to follow‐up (n = 124), and missing records (n = 120). Baseline characteristics of the patients are summarized in Table [1](#agm212023-tbl-0001){ref-type="table"}. The parallel‐opposed technique was used to treat pelvis and extremity, while the direct posterior technique was used to treat spine. Treatment was delivered with a linear accelerator using megavoltage beams.

###### 

Baseline characteristics of patients

                                                                     Single fraction (N = 65)   Multiple fraction (N = 97)   All patients (N = 162)                 
  ------------------------------------------------------------------ -------------------------- ---------------------------- ------------------------ ------ ------ ------
  Age                                                                                                                                                               
  \< 65                                                              41                         63                           72                       74.2   113    69.8
  ≥65                                                                24                         37                           25                       25.8   49     30.2
  Mean                                                               58.9                                                    54.9                            56.6   
  Median                                                             60.0                                                    55.0                            57     
  Sex                                                                                                                                                               
  Male                                                               20                         30.8                         34                       35     54     33.3
  Female                                                             45                         69.2                         63                       65     108    66.7
  ECOG                                                                                                                                                              
  1                                                                  37                         57                           57                       58.8   94     58
  2                                                                  22                         33.8                         36                       37.1   58     35.8
  3                                                                  6                          9.2                          4                        4.1    10     6.2
  Comorbidities                                                                                                                                                     
  Yes                                                                17                         26.2                         20                       20.6   37     22.8
  No                                                                 48                         73.8                         77                       79.4   125    77.2
  Primary tumor                                                                                                                                                     
  Breast                                                             33                         50.8                         51                       52.6   84     51.9
  Lung                                                               16                         24.6                         15                       15.5   31     19.1
  Prostate                                                           7                          10.8                         12                       12.4   19     11.7
  Others                                                             9                          13.8                         19                       19.5   28     17.3
  Extent of bone metastases                                                                                                                                         
  Single                                                             6                          9.2                          3                        3.1    9      5.6
  Multiple                                                           59                         90.8                         94                       96.9   153    94.4
  Visceral metastases                                                                                                                                               
  Yes                                                                31                         47.7                         42                       43.3   73     45.1
  No                                                                 34                         52.3                         55                       56.7   89     54.9
  Baseline pain score[a](#agm212023-note-0001){ref-type="fn"}                                                                                                       
  2                                                                  1                          1.5                          2                        2.1    3      1.9
  3                                                                  36                         55.4                         52                       53.6   88     54.3
  4                                                                  28                         43.1                         43                       44.3   71     43.8
  Baseline analgesic score[b](#agm212023-note-0002){ref-type="fn"}                                                                                                  
  2                                                                  13                         20                           16                       16.5   29     17.9
  3                                                                  29                         44.6                         47                       48.5   76     46.9
  4                                                                  23                         35.4                         34                       35     57     35.2
  Treatment site                                                                                                                                                    
  Spine                                                              29                         44.6                         62                       63.9   91     56.2
  Pelvis                                                             25                         38.5                         30                       30.9   55     34.0
  Extremities                                                        5                          7.7                          2                        2.1    7      4.3
  Others                                                             4                          6.2                          5                        5.2    9      5.5
  Systemic therapy                                                                                                                                                  
  Yes                                                                52                         80                           79                       81.4   131    80.9
  No                                                                 13                         20                           18                       18.6   31     19.1
  Fractionation schedule                                                                                                                                            
  10 Gy in 1\#                                                       ‐                          ‐                            ‐                        ‐      5      3.1
  8 Gy in 1\#                                                        ‐                          ‐                            ‐                        ‐      60     37
  30 Gy in 10\#                                                      ‐                          ‐                            ‐                        ‐      5      3.1
  20 Gy in 5\#                                                       ‐                          ‐                            ‐                        ‐      92     56.8

There were no patients with pain score 1.

There were no patients with analgesic score 0‐1.
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3.2. Pain response according to fractionation group {#agm212023-sec-0015}
---------------------------------------------------

The mean baseline pain and analgesic score at the treated site were 3.4 (SD ± 0.5) and 3.2 (SD ± 0.7), respectively. Response evaluation according to treatment groups is shown in Table [2](#agm212023-tbl-0002){ref-type="table"}. There was an increasing trend of pain score response and analgesic score response noted in both the treatment groups from 4 to 24 weeks. Using chi‐square test, the difference in response rates between the 2 treatment groups was not statistically significant. However, there was a statistically significant difference in analgesic score progression between the 2 fractionation groups seen at 24 weeks, *P* = .019. When the results were reported in terms of International Consensus Endpoint, the difference in overall response rates and pain progression between the 2 treatment groups was not statistically significant.

###### 

Response according to treatment group

                                     Total, N = 162    Single fraction, N = 65                                 Multiple fraction, N = 97   *P*‐value
  ---------------------------------- ----------------- ------------------------------------------------------- --------------------------- ----------------------------------------------
  Pain score response                                                                                                                      
  4 wk                               129/162 (79.6%)   50/65[a](#agm212023-note-0004){ref-type="fn"} (76.9%)   79/97 (81.4%)               .394
  12 wk                              138/159 (86.8%)   54/63 (85.7%)                                           84/96 (87.5%)               .938
  24 wk                              136/158 (86.1%)   51/62 (82.3%)                                           85/96 (88.5%)               .228
  Pain score progression                                                                                                                   
  4 wk                               6/162 (3.7%)      4/65 (6.2%)                                             2/97 (2.1%)                 .176
  12 wk                              5/159 (3.1%)      2/63 (3.2%)                                             3/96 (3.1%)                 .986
  24 wk                              11/158 (6.9%)     4/62 (6.5%)                                             7/96 (7.3%)                 .839
  Analgesic score response                                                                                                                 
  4 wk                               81/162 (50%)      30/65 (46.2%)                                           51/97 (52.6%)               .155
  12 wk                              92/159 (57.9%)    34/63 (54%)                                             58/96 (60.4%)               .319
  24 wk                              93/158 (58.9%)    34/62 (54.8%)                                           59/96 (61.5%)               .056
  Analgesic score progression                                                                                                              
  4 wk                               16/162 (9.9%)     10/65 (15.4%)                                           6/97 (6.2%)                 .054
  12 wk                              20/159 (12.6%)    11/63 (17.5%)                                           9/96 (9.4%)                 .133
  24 wk                              27/158 (17.1%)    16/62 (9.9%)                                            11/96 (11.5%)               .019[b](#agm212023-note-0005){ref-type="fn"}
  International consensus endpoint                                                                                                         
  4 wk                                                                                                                                     
  CR                                 52/162 (32.1%)    18/65 (27.7%)                                           34/97 (35.1%)               
  PR                                 39/162 (24.1%)    15/65 (23.1%)                                           24/97 (24.7%)               
  ORR                                92/162 (56.2%)    33/65 (50.8%)                                           58/97 (59.8%)               .364
  Progression                        54/162 (33.3%)    22/65 (33.8%)                                           32/97 (33.0%)               .910
  12 wk                                                                                                                                    
  CR                                 55/159 (34.6%)    21/63 (33.3%)                                           34/96 (35.4%)               
  PR                                 44/159 (27.7%)    18/63 (28.6%)                                           26/96 (27.1%)               
  ORR                                99/159 (62.3%)    39/63 (61.9%)                                           60/96 (62.5%)               .466
  Progression                        38/159 (23.9%)    13/63 (20.6%)                                           25/96 (26.0%)               .384
  24 wk                                                                                                                                    
  CR                                 89/158 (56.3%)    33/62 (53.2%)                                           56/96 (58.3%)               
  PR                                 14/158 (8.9%)     5/62 (8.1%)                                             9/96 (9.4%)                 
  ORR                                103/158 (65.2%)   38/62 (61.3%)                                           65/96 (67.7%)               .259
  Progression                        28/158 (17.7%)    10/62 (16.1%)                                           18/96 (18.8%)               .599

CR, complete response; PR, partial response; ORR, overall response (CR + PR).

Number of patients within treatment group.

*P* \< .05.
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3.3. Factors affecting pain response {#agm212023-sec-0016}
------------------------------------

Several factors that could potentially affect overall pain response at 4 weeks were analyzed using simple logistic regression. The univariate analysis is shown in Table [3](#agm212023-tbl-0003){ref-type="table"}, and using the preliminary main‐effect model (*P* \< .25), this suggests that gender, ECOG, primary tumor, and bone‐targeting agent could possibly be significant prognostic factors affecting pain response, with significantly different rates of overall pain response, when other confounders are not adjusted.

###### 

Univariate analysis of prognostic factors and overall pain response

  Variable                    Odds ratio   95% confidence interval   Wald statistic   *P*‐value
  --------------------------- ------------ ------------------------- ---------------- ------------------------------------------------
  Age                                                                                 
  \< 65                       1.000        ‐                         ‐                ‐
  ≥65                         1.193        0.605‐2.353               0.258            .611
  Gender                                                                              
  Male                        1.000        ‐                         ‐                ‐
  Female                      1.823        0.942‐3.527               3.178            .075[a](#agm212023-note-0006){ref-type="fn"}
  ECOG                                                                                
  \< 2                        3.240        1.689‐6.213               12.526           \<.001[a](#agm212023-note-0006){ref-type="fn"}
  ≥2                          1.000        ‐                         ‐                ‐
  Primary tumor                                                                       
  Breast                      5.000        1.959‐12.762              11.333           .001[a](#agm212023-note-0006){ref-type="fn"}
  Lung                        2.344        0.795‐6.908               2.385            .122[a](#agm212023-note-0006){ref-type="fn"}
  Prostate                    4.286        1.238‐14.831              5.279            .022[a](#agm212023-note-0006){ref-type="fn"}
  Others                      1.000        ‐                         ‐                ‐
  Extent of bone metastases                                                           
  Single                      1.000        ‐                         ‐                ‐
  Multiple                    1.027        0.265‐3.973               0.001            .969
  Treatment site                                                                      
  Spine                       1.067        0.269‐4.235               0.008            .927
  Pelvis                      1.033        0.250‐4.269               0.002            .964
  Extremities                 0.600        0.082‐4.400               0.253            .615
  Others                      1.000        ‐                         ‐                ‐
  Fractionation                                                                       
  Single                      1.000        ‐                         ‐                ‐
  Multiple                    1.299        0.690‐2.446               0.658            .417
  Bone‐targeting agent                                                                
  Yes                         1.693        0.898‐3.192               2.650            .104[a](#agm212023-note-0006){ref-type="fn"}
  No                          1.000        ‐                         ‐                ‐
  Systemic treatment                                                                  
  Yes                         1.256        0.573‐2.752               0.323            .570
  No                          1.000        ‐                         ‐                ‐

The variables selected (*P* \< .25) for the preliminary main‐effect model are gender, ECOG, primary tumor, and bone‐targeting agent.
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For these variables, forward and backward logistic regression was carried out. Following this, only 2 of the variables, that is primary tumor and ECOG, were found to be significant in the main‐effect model, as shown in Table [4](#agm212023-tbl-0004){ref-type="table"}. There is no interaction and multicollinearity seen among the variables. The Hosmer and Lemeshow test is significant at 0.492 (\>0.05). The logistic regression has a Nagelkerke *R* ^2^ of 0.202.

###### 

Multivariate analysis for overall response

  Variable        Adjusted odds ratio (aOR)   95% confidence interval   Wald statistic   *P*‐value
  --------------- --------------------------- ------------------------- ---------------- -----------
  ECOG                                                                                   
  \< 2            3.405                       1.708‐6.790               12.112           .001
  ≥2              1.000                       ‐                         ‐                ‐
  Primary tumor                                                                          
  Breast          5.231                       1.973‐13.869              11.064           .001
  Lung            2.817                       0.907‐8.747               3.210            .073
  Prostate        5.522                       20.420‐6.557              6.557            .010
  Others          1.000                       ‐                         ‐                ‐

John Wiley & Sons, Ltd

3.4. Retreatment {#agm212023-sec-0017}
----------------

The overall retreatment rate was 20.4% (n = 33). Retreatment was observed in 16 patients (24.6%) in the single fraction group and 17 patients (17.5%) in the multiple fraction group. Although the retreatment rate was higher in the single fraction group, this was not statistically significant (*P* = .552). Mean duration to retreatment was 35.1 (SD ± 22.4) weeks in the single fraction group and 57.6 (SD ± 54) weeks in the multiple fraction group. Using Mann‐Whitney *U* test, there was no statistically significant difference in mean duration to retreatment in the 2 groups (*P* = .656). At evaluation period of 24 weeks, 11 (33.3%) patients had retreatment. The main reason for retreatment was worsening pain seen in 16 (48.5%) patients, cord compression with pain in 14 (42.4%) patients, and pathological fracture with pain in 3 (9.1%) patients.

3.5. Symptomatic skeletal events {#agm212023-sec-0018}
--------------------------------

The occurrence of pathological fracture in the treated site was seen in 4 (2.5%) patients, 2 (3%) patients in the single fraction group and 2 (2.1%) patients in the multiple fraction group. Spinal cord compression was seen in 14 (8.6%) patients, 5 (7.7%) patients in the single fraction group, and 9 (9.3%) patients in the multiple fraction group. There was no significant difference in the occurrence of SSEs between the 2 treatment groups, *P* = 1.00.

3.6. Bone metastases {#agm212023-sec-0019}
--------------------

Mean time from diagnosis of bone metastases to first irradiation for pain was 20.2 weeks (SD ± 40.3 weeks). Mean duration of diagnosis of bone metastases to first irradiation was 14.3 weeks (SD ± 18) in the single fraction group and 24.11 (SD ± 49.7) weeks in the multiple fraction group. Using Mann‐Whitney *U* test, there was no significant difference in duration of diagnosis of bone metastases to time of first irradiation between single and multiple fractionation group (*P* = .492).

3.7. Bone‐targeting agents and systemic therapy {#agm212023-sec-0020}
-----------------------------------------------

The administration of bone‐targeting agent and systemic therapy in both the fractionation groups is shown in Table [5](#agm212023-tbl-0005){ref-type="table"}. Mean time from diagnosis of bone metastases to initiation of bone‐targeting agent was 44.9 (SD ± 58) weeks. There was a significant association for usage of bone‐targeting agents and occurrence of pathological fracture and cord compression (*P* = .004).

###### 

Concomitant therapy according to fractionation group

                                   Single fraction (N = 65) (%)                        Multiple fraction (N = 97) (%)                      Total (N = 162) (%)                                 Retreatment (N = 33)                                *P*‐value[f](#agm212023-note-0012){ref-type="fn"}   Pathological fracture/Cord compression (N = 18) (%)   *P*‐value[g](#agm212023-note-0013){ref-type="fn"}
  -------------------------------- --------------------------------------------------- --------------------------------------------------- --------------------------------------------------- --------------------------------------------------- --------------------------------------------------- ----------------------------------------------------- ---------------------------------------------------
  Bone‐targeting agents (N = 71)   29 (44.6)[a](#agm212023-note-0007){ref-type="fn"}   42 (43.3)[a](#agm212023-note-0007){ref-type="fn"}   71 (43.8)[b](#agm212023-note-0008){ref-type="fn"}   12 (36.4)[c](#agm212023-note-0009){ref-type="fn"}   .43                                                 2 (11.1)[d](#agm212023-note-0010){ref-type="fn"}      .004[e](#agm212023-note-0011){ref-type="fn"}
  Pamidronate                      2 (3.1)                                             4 (4.1)                                             6 (3.7)                                                                                                                                                                                                           
  Zoledronic A.                    24 (36.9)                                           33 (34.0)                                           57 (35.2)                                                                                                                                                                                                         
  Denosumab                        3 (4.6)                                             5 (5.2)                                             8 (4.9)                                                                                                                                                                                                           
  Systemic therapy (N = 131)       52 (80)                                             79 (81.4)                                           131 (80.9)                                          28 (84.8)                                           .625                                                15 (83.3)                                             1.000
  Chemotherapy                     32 (49.2)                                           40 (41.2)                                           72 (44.4)                                                                                                                                                                                                         
  Hormonal therapy                 15 (23.1)                                           32 (33)                                             47 (29)                                                                                                                                                                                                           
  Tyrosine kinase inhibitor        5 (7.7)                                             5 (5.2)                                             10 (6.2)                                                                                                                                                                                                          
  Radioiodine therapy              0 (0)                                               2 (2.1)                                             2 (1.2)                                                                                                                                                                                                           

Percent within treatment group.

Percent within total number of patients.

Percent within retreatment.

Percent within pathological fracture/cord compression.

*P* \< .05.

*P*‐value for retreatment.

*P*‐value for pathological fracture/cord compression.
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4. DISCUSSION {#agm212023-sec-0021}
=============

The results of our study showed that there is no significant difference in pain relief between single and multiple fraction radiotherapy for palliation of painful bone metastases. This is consistent with several published studies[5](#agm212023-bib-0005){ref-type="ref"}, [6](#agm212023-bib-0006){ref-type="ref"}, [7](#agm212023-bib-0007){ref-type="ref"} and meta‐analyses.[10](#agm212023-bib-0010){ref-type="ref"}, [11](#agm212023-bib-0011){ref-type="ref"} Although we employed the verbal rating scale which is less sensitive than the numerical rating scale,[17](#agm212023-bib-0017){ref-type="ref"} it is a reliable method for pain assessment.[18](#agm212023-bib-0018){ref-type="ref"} Pain response rates from trials which used a categorical scale as a measure of pain showed response rates of 76%,[14](#agm212023-bib-0014){ref-type="ref"} 72%,[7](#agm212023-bib-0007){ref-type="ref"} 83.7%[5](#agm212023-bib-0005){ref-type="ref"} in the single fraction group and 84%,[14](#agm212023-bib-0014){ref-type="ref"} 90%,[7](#agm212023-bib-0007){ref-type="ref"} 89.2%[5](#agm212023-bib-0005){ref-type="ref"} in the multiple fraction group. This is compatible with our pain response rates of 76.9%‐85.7% in the single fraction group and 81.4%‐88.5% in the multiple fraction group. A recent systematic review[19](#agm212023-bib-0019){ref-type="ref"} comparing various single fraction doses for the palliation of painful bone metastases showed a higher overall response rate for higher doses, that is an overall response rate of 84% for 10 Gy and 72% for 8 Gy in evaluable patients, which was representative of the single fraction doses that were used in our study, as 92.3% of our patients were prescribed 8 Gy and the remaining 10 Gy.

When results were reported using International Consensus Endpoints, we obtained an overall response rate of 56.2% and 62.3% at 4 and 12 weeks, respectively, in the entire cohort of patients. Our results were comparable with published data of overall response rates in evaluable patients according to International Consensus Endpoint at 1 month of 58% and 3 months of 67%.[20](#agm212023-bib-0020){ref-type="ref"} The reported estimated spinal adverse event (SAE) rate (which include uncontrolled pain) of \>40% at 6 months[21](#agm212023-bib-0021){ref-type="ref"} could explain the significant requirement for more analgesia at 24 weeks that was seen in our study.

There was a significantly higher overall response rate observed in patients with ECOG \< 2 and primary tumors of breast and prostate when compared to other primary tumors, which was compatible with evidence which demonstrated that patients with breast and prostate cancer had the best response rate.[9](#agm212023-bib-0009){ref-type="ref"}

In addition to this, a study has reported that the single fraction group was associated with fourfold greater retreatment rate and higher pathological fracture rate.[9](#agm212023-bib-0009){ref-type="ref"} Our study did not demonstrate this. We found higher retreatment rates in the single fraction group, but this was not statistically significant. We obtained a retreatment rate of 24.6% in the single fraction group and 17.5% in the multiple fraction group, which was higher as compared to published data of 21%,[19](#agm212023-bib-0019){ref-type="ref"} 18.2%[21](#agm212023-bib-0021){ref-type="ref"} in single fraction group and 6%[21](#agm212023-bib-0021){ref-type="ref"} in the multiple fraction group. The highest percentage of retreatment was seen in patients with lung primary, which could be due to the effect of tumor histology.[9](#agm212023-bib-0009){ref-type="ref"}, [12](#agm212023-bib-0012){ref-type="ref"} At 4 weeks of evaluation endpoint, there were 3 (9%) retreatments involving the spine, 2 of them were in the single fraction group. The use of single fraction radiotherapy in patients with high spinal instability neoplastic score (SINS ≥ 11) was associated with higher incidence of SAEs, with a reported cumulative incidence first with SAE rate at 30 days of 6.8% in the single fraction group and 3.5% in the multiple fraction group.[21](#agm212023-bib-0021){ref-type="ref"}

Our results showed a lower pathological fracture rate of 3% in the single fraction group compared to 4%[9](#agm212023-bib-0009){ref-type="ref"}, [19](#agm212023-bib-0019){ref-type="ref"} and 13.6%[21](#agm212023-bib-0021){ref-type="ref"} that have been reported. However, the pathological fracture rate obtained in the multiple fraction group of 2.1% was similar to published data of 2%[9](#agm212023-bib-0009){ref-type="ref"} and 3%.[21](#agm212023-bib-0021){ref-type="ref"} As for cord compression rate, we obtained rates of 7.7% in the single fraction group and 9.3% in the multiple fraction group compared to that reported in trials, that is, 3% to 7%,[19](#agm212023-bib-0019){ref-type="ref"} 10.5%[21](#agm212023-bib-0021){ref-type="ref"} in single fraction group and 1.7%[21](#agm212023-bib-0021){ref-type="ref"} in the multiple fraction group. The low spinal cord compression rate in the multiple fraction group[21](#agm212023-bib-0021){ref-type="ref"} may not be accurate as the recruitment of patients was not reflective of the true numbers of spinal cord compression cases. Furthermore, this trial only assessed patients that had spinal radiotherapy, which only account for 56.2% of our study patients.

The significant association between the development of pathological fracture and cord compression with the usage of bone‐targeting agents is consistent with published trials on the efficacy of bone‐targeting agents in reducing the risk of skeletal‐related events.[22](#agm212023-bib-0022){ref-type="ref"}, [23](#agm212023-bib-0023){ref-type="ref"}

There were several limitations to our study. Given the retrospective nature of this study, we were limited by the availability of data. Firstly, as our primary objective was to assess pain response, patients who did not have data or follow‐up notes following irradiation were excluded. This included patients who had died within evaluation period of 24 weeks. We acknowledge that the number of deaths reported in this study may not be accurate as there could be more deaths in the lost to follow‐up and missing notes group that we were not able to trace. Hence, our study population may not be representative of the actual situation.

Secondly, we realized that patient‐reported outcomes were as important as physician‐assessed outcomes, as it provides evaluation of response on the patient\'s perspective. Results based on patient‐reported outcomes showed an improvement of 70% in pain with no difference between single and multiple fraction groups.[24](#agm212023-bib-0024){ref-type="ref"}

The choice of single fraction radiotherapy is affected by cultural differences, physicians' experience, location of training, and practice location.[25](#agm212023-bib-0025){ref-type="ref"} The reported single fraction utilization rate in Canada was 49.2%,[25](#agm212023-bib-0025){ref-type="ref"} as compared to the United States of 4.7%.[26](#agm212023-bib-0026){ref-type="ref"} There are no trials reporting on the single fraction utilization rate in Asian countries to date. As for cultural differences, 76% of Canadian patients favored single fraction[27](#agm212023-bib-0027){ref-type="ref"} while 85% of Asian patients preferred the multiple fraction schedule.[28](#agm212023-bib-0028){ref-type="ref"} Patients' preference toward treatment needs to be considered as well as 84% of Asian patients expressed positive opinions about being involved in the decision‐making process.[28](#agm212023-bib-0028){ref-type="ref"}

Therefore, our study could be improved by including outcome assessment by physician and patient, SINS for patients with spinal metastases, patient involvement in treatment decision making, and exploration on physician judgment in choosing radiotherapy prescription. A prospective randomized trial should be performed in the future to verify our results. Importantly, despite our limitations, we were able to obtain comparable pain response rates to those found in the literature.

In conclusion, our study showed that there is no significant difference in terms of pain response, retreatment rate, and SSEs between single fraction and multiple fraction radiotherapy in patients treated for uncomplicated bone metastases. Single fraction radiotherapy should be the standard treatment and prescribed more frequently as it is more convenient and cost‐effective.
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